<DOC>
	<DOCNO>NCT02313740</DOCNO>
	<brief_summary>Prospective cohort study evaluate safety immunogenicity fragment , inactivated trivalent Influenza vaccine produce Butantan Institute healthy adult elderly . The study include total 120 participant : 60 participant age 18 59 year healthy adult group , 60 participant age old 60 year elderly group.This study evaluate safety one dose fragment , inactivated trivalent Influenza vaccine first 3 day vaccination , well immunogenicity 21 day vaccination .</brief_summary>
	<brief_title>Prospective Cohort Study Evaluate Safety/Immunogenicity Butantan Influenza Vaccine Healthy Adults/Elderly</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult , male female age 18 59 Elderly age 60 year complete To available participate study throughout duration ( approximately 21 day ) To medical indication vaccinate influenza To demonstrate intention participate study , document signature study´s inform consent form . Evidence active neurological , cardiac , pulmonary , hepatic renal disease clinical history and/or physical examination ( except hypertension control among elderly ) Compromised immune system diseases include : HIV , diabetes mellitus , cancer ( except basal cell carcinoma ) autoimmune diseases Behavioral , cognitive psychiatric disease opinion principal investigator representative physician , affect participant ability understand cooperate study protocol requirement Abusive usage alcohol drug past 12 month cause medical , professional family problem , indicate clinical history Known systemic hypersensitivity egg component vaccine History severe adverse reaction previous administration Influenza vaccine within 6 week follow vaccination History GuillainBarre Syndrome demyelinate disease Diagnosis asthma history hospitalization last six month due illness Suspected confirm fever 3 day prior vaccination axillary temperature great 37.8 ° C day vaccination Use corticosteroid ( except topical nasal ) immunosuppressive drug within 42 day study initiation/baseline . It consider immunosuppressive dose corticosteroid equivalent dose ≥10 mg prednisone per day 14 day Impaired coagulation due chronic disease due use anticoagulant medication ( warfarin heparin ) 7 day precede vaccination Have receive live virus vaccine within 28 day kill virus vaccine last 14 day prior vaccination , schedule immunization first 21 day vaccination Have receive influenza vaccine past 6 month ; History asplenia Have receive blood product past 6 month , include transfusion immunoglobulin , schedule administration blood product immunoglobulin first 21 day vaccination counterindication Influenza vaccination , include allergy egg protein Use investigational product within 42 day vaccination ; Any condition might put risk safety/rights potential participant hurdle his/her compliance protocol investigator 's opinion representative physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza Vaccines</keyword>
</DOC>